
## U.S. Pharmacopeia method



## Repaglinide : Enantiomeric Purity



Column	: CHIRALPAK <sup>®</sup> AGP 0.40cmФ × 10cmL (L41)		
Solution A	: Buffer 💥		
Solution B	: Acetonitrile		
Mobile phase	: See below table		
Flow rate	: 1.0mL/min.		
Injection volume	: 10µL		
UV detection	: 240nm		
* Buffer Dissolve 1	g of monobasic potassium phosphate in 11 of water	If needed	adjust with

 Buffer : Dissolve 1 g of monobasic potassium phosphate in 1 L of water. If needed, adjust with 2 N Sodium hydroxide or with dilute phosphoric acid to a pH of 4.7

(Table)


Time	fime Solution A Solutio			
(min)	(%)	(%)		
0	80	20		
4	60	40		
6	60	40		

System suitability

System suitability solution: 1.0 mg/mL of USP Repaglinide RS and 0.02 mg/mL of USP Repaglinide Related Compound E RS in methanol.

Standard solution: 2.0 µg/mL of USP Repaglinide Related Compound E RS in methanol.

Relative retention time: Repaglinide and Repaglinide Related Compound E are 1.0 and 1.5, respectively.



	Requirement	Result
Resolution (System suitability solution)	≧1.5	5.5
Relative standard deviation ( <i>Standard solution</i> )	≦5.0%	0.25%